Objective-The protein degrading activity of cathepsin C (CatC), combined with its role in leukocyte granule activation, suggests a contribution of this cystein protease in atherosclerosis. However, no experimental data are available to validate this concept. Approach and Results-CatC gene and protein expression were increased in ruptured versus advanced stable human carotid artery lesions. To assess causal involvement of CatC in plaque progression and stability, we generated LDLr
C athepsin C (CatC), also known as dipeptidyl peptidase I, is a lysosomal cystein protease that belongs to the papain super family. 1 Unlike cathepsin S (CatS) and cathepsin K (CatK), it is expressed in many tissues, but highest in lymphoid organs, such as spleen, 2 and homologues have been identified in a variety of species, suggesting an important and widespread role. [2] [3] [4] [5] [6] In mice, CatC is most abundantly expressed in lung, liver, spleen, and small and large intestines; intermediately expressed in bone marrow, thymus, and stomach; and low expression in kidney, heart, and brain. 7 CatC has a unique aminodipeptidyl peptidase activity 2 and can progressively remove N-terminal dipeptides from various protein substrates and as such participates in post-translational processing. Indeed, studies in CatC knockout mice have revealed a central function in the activation of granule serine proteases in cytotoxic T lymphocytes and natural killer cells (granzymes A and B), mast cells (chymase and tryptase), and neutrophils (cathepsin G, proteinase 3, and elastase). 2, [8] [9] [10] [11] Furthermore, alveolar macrophage and mast cell-derived CatC were seen to cleave extracellular matrix proteins, such as fibronectin and collagen types I, III, and IV, suggestive of a role of CatC in airway remodeling of chronic airway diseases, such as asthma. 12 Finally, a contribution of CatC in coagulation as plasminogen 13 and thrombin regulator 14 and in angiogenesis have been documented. 15 CatC-deficient mice seem healthy but have defects in serine protease activities in multiple hematopoietic lineages 9 and show unexpected resistance to sepsis as compared with their wildtype (WT) littermates, possibly by attenuated tryptase-dependent IL-6 cleavage. 16 Likewise, CatC −/− mice are protected against acute arthritis by reducing neutrophil recruitment to the joints, as well as by modulating the neutrophil production of cytokines and possibly chemokines. 8, 17 Its immunomodulatory effects on mast cells, macrophages, and neutrophils next to its intrinsic proteolytic capacity points to a role of CatC in inflammatory vascular remodeling processes. Indeed, CatC was seen to regulate neutrophil recruitment and CXCL12 production in January 2015 elastase-induced abdominal aortic aneurysm formation. 18 Although several cathepsins, such as CatS, 19 CatK, 20 and cathepsin L, 21 have already been implicated in atherosclerosis, the effect of CatC in its pathophysiology remains elusive, apart from its identification as a sensitive vascular injury marker in rabbits with experimental hypertension and cholesterol-fed mini pigs. 22, 23 Here, we show increased CatC gene and protein expression in advanced stable compared with ruptured carotid human atherosclerotic plaques, mainly localizing in macrophages. Furthermore, we provide evidence for an attenuated atherogenic response in low-density lipoprotein receptor-deficient (LDLr −/− ) mice with hematopoietic deficiency of CatC, via a selective tuning of innate and adaptive immune responses.
Materials and Methods

Materials and Methods are available in the online-only Data Supplement
Results
CatC Is Differentially Expressed in Ruptured Human Atherosclerotic Plaques
In a candidate approach using microarray analysis, the cathepsin family was identified as differentially expressed between stable and ruptured segments of the same plaque (all P<0.001; Figure 1A ). Giving its immunomodulatory effects, proteolytic capacity, and unknown role in atherosclerosis, we focused our follow-up research on CatC. Protein expression was validated on a series of early, stable, and ruptured human carotid plaques ( Figure 1B ). CatC expression localized to the same areas with abundant CD68
+ macrophages presence ( Figure 1B , panel iii and iv). CatC was expressed significantly higher in ruptured plaques compared with both stable (P<0.05) and early plaques (P<0.05; Figure I in the online-only Data Supplement).
LDLr −/− Mice With Hematopoietic CatC Deficiency Display Reduced Atherosclerosis
To address the causal involvement of CatC in atherogenesis, we generated LDLr −/− chimeras with hematopoietic CatC deficiency by a bone marrow transplantation strategy. After recovery, mice were put on a high fat diet for 13 weeks and equipped with semiconstrictive carotid artery collars after 6 weeks of high fat diet to induce lesion formation. Body weight and plasma total cholesterol levels did not differ between groups throughout the experiment ( Figure  II in the online-only Data Supplement). At point of killing, lesion formation was analyzed at 4 sites: the common carotid artery, the aortic arch, the aortic root (all cross-sectional), and the descending aorta (en face). Carotid artery plaques were 55% smaller in CatC −/− chimeras compared with WT controls (P<0.05; Figure 2B ) and had smaller lipid core areas ( Figure  IIIB in the online-only Data Supplement). A representative picture of the carotid lesions is shown in Figure 2A .
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The aortic arch showed a similar pattern with reduced plaque size in CatC −/− chimeras. Plaque area of the early lesions was decreased in the CatC −/− chimeras (P=0.009; Figure IVA in the online-only Data Supplement), whereas advanced lesion size did not differ between groups ( Figure  IVB in the online-only Data Supplement). Consequently, the early and total plaque burden (mean number of aortic arch lesions per mouse) was reduced in CatC −/− chimeras, but advanced lesion burden was unaltered ( Figure IVC in the online-only Data Supplement). Given the observations in the advanced plaques of the aortic arch, an additional location was investigated: the lesions of the aortic root. In the advanced lesions of the aortic root, both lesion size (P<0.05; Figure 2C ) and necrotic core content (P<0.05; Figure 2D ) were smaller in the CatC −/− chimeras. En face analysis of the thoracic and abdominal aorta showed the scanty presence of lipid deposits that had not progressed beyond the early stage. Consistent with the carotid and aortic arch data, the WT group presented a larger area of initial fatty streak lesions compared with the CatC −/− chimeras (P=0.009; Figure IVD in the online-only Data Supplement).
Further morphometric analysis of the carotid lesions did not show any effects of hematopoietic CatC deficiency on lumen area, media area, and total vessel area (data not shown). Zooming in on plaque composition, we first quantified the contribution of hematopoietic CatC to total plaque CatC. Clearly, almost all plaque CatC was derived from leukocytes, as CatC expression was almost abrogated in CatC −/− chimera plaques, whereas it was predominant in foam cells and macrophages of WT plaques ( Figure 3A ; Figure IIIA in the onlineonly Data Supplement). In fact, only 18% of the lesions of the CatC −/− chimara mice showed CatC staining, while 93% of the WT lesions showed robust CatC staining. Of interest, we did observe scanty CatC expression in the carotid adventitia, colocalizing with granular cells, possibly mast cells, and resident macrophages (see arrows; Figure 3A ). In concert with the low plaque CatC expression in CatC −/− chimeras, CatC activity was extremely low in aortic arch tissue homogenates of CatC −/− chimeras, whereas elastolytic activity was comparable to WT ( Figure 3B and 3C).
Compatible with the reduced plaque progression, CatC 
Effects of CatC Deficiency on Monocyte/ Macrophage Function
The profound reduction in plaque size, the rather subtle effects on plaque composition and the abundant expression of CatC by plaque macrophages, foam cells, and granulocytes, prompted further study of monocyte/macrophage function in CatC deficiency. We found that CD11b + Ly6G
− blood monocyte levels tended to be increased in CatC −/− mice, albeit not significantly ( Figure VA in the online-only Data Supplement).
As the number of macrophages in plaques did not differ significantly between WT and CatC −/− chimeras, we next examined whether CatC expression affects or is affected by macrophage polarization. As expected, CatC −/− bone marrowderived macrophages (BMDM), whether at baseline (M0) or IL-4 (M2) or IFN-γ primed (M1), did not express CatC ( Figure 4A ). However, CatC expression is upregulated >20-fold in WT M1 macrophages (P<0.001), and, conversely, downregulated by >70% in WT M2 (P<0.01; Figure 4A ). Thus, CatC seems to be a selective M1 marker.
CatK and CatS were next measured to verify whether any of these proteases are overexpressed to compensate for CatC deficiency and potentially contribute to the CatC phenotype. The results obtained show that CatS but not CatK expression is slightly but significantly increased in CatC Figure 4D ; P<0.05), supporting the hypothesis that M2 polarization in vitro is favored in the absence of CatC. To further investigate this phenomenon, immunohistochemical stainings for a M1 marker (iNOS) and a M2 marker (Arg-1) were performed on the initial collar-induced carotid lesions and advanced aortic root lesions. M1 macrophages were more dominant both in early and advanced lesions, this in contrast to a report of Khallou-Laschet et al, that showed a predominance of M2 macrophages in early lesions. 24 An increased expression of the M2 marker was evident in the advanced aortic root lesions ( Figure VI in the online-only Data Supplement). There was no difference in M1 and M2 presence in the carotid and aortic root lesions of the WT and CatC −/− chimeras. Thus, despite the clear in vitro M2 phenotype of CatC −/− BMDM, this did not lead to a higher presence of M2 macrophages in the lesions of the CatC −/− chimeras, albeit that we used a limited panel of M1/M2 markers and assessed only 1 (end) timepoint.
Congruent with the M2 skewed macrophage polarization observed in CatC deficiency, of the 7 cytokines detectable in plasma of WT and CatC −/− chimeras, on chow and high fat diet, only eotaxin levels differed between both groups. High fat diet upregulated plasma eotaxin in CatC −/− (P<0.01), but not WT chimeras ( Figure 5A ). Moreover, TGF-β as well as eotaxin expression by spleen was increased in CatC −/− chimeras (P<0.01; Figure 5B and 5C).
Macrophage polarization is a major determinant of the cell's phagocytotic capacity. However, the CatC-dependent shift in macrophage polarity was not accompanied by an altered ability to ingest or accumulate DiI-labeled LDL or oxLDL ( Figure In addition, when testing cell migration/tissue repair in BMDM, we found no difference between the groups in any of the conditions tested (no stimulation, LPS stimulation, and data not shown).
Altogether, the above data point to autocrine-positive feedback of CatC in macrophage polarization toward M1.
Peripheral Effects on T-Cell Function
The increased eotaxin and TGF-β expression in CatCdeficient mice might also be reflective of or affect Th2-skewed T-cell responses. We did observe increased CD4 and lower CD8 numbers in lymph node and blood with CatC deficiency. Hence, CD4/CD8 ratios were elevated in both tissues of CatC 
Discussion
CatC is reported to exert immunomodulatory effects on mast cells, macrophages, and neutrophils, which next to its intrinsic proteolytic capacity points to a potential role of CatC in inflammatory vascular remodeling processes, such as atherosclerosis. We show here that CatC is not only upregulated with lesion progression in human atherosclerotic lesions, but may also be causally involved in the pathogenesis of this disease. Hematopoietic CatC deficiency led to attenuated lesion formation in the carotid artery, the aortic arch, and the descending aorta in our mouse model. Although CatC expression appeared to be reflective of macrophage M1 polarization, it surprisingly fostered an autocrine-positive feedback loop for M1 polarization in vitro. Combined with the CatC deficiencyassociated Th2 skewing, this effect may well be responsible for the observed phenotype.
In our study, the results pointed to a T cell-dependent effect of leukocyte CatC deficiency in lesion development. This is in contrast to the effect of CatC deficiency in a model of collagen-induced arthritis. 17 Here, CatC deficiency reduced the development of collagen-induced arthritis, independently of T cell and B cell function. Specific measures of humoral immunity (IgG1 and IgG2a anticollagen antibodies) were comparable in WT and CatC −/− mice as was ConA-induced T cell proliferation. These are specific parameters of T and B cell function, which do not exclude difference in the parameters that were assessed in our atherosclerosis study. In addition, in our model, T cell proliferation was comparable in the WT and CatC −/− chimeric mice (data not shown). Thus, the mechanism via which CatC modulate disease outcome may differ in distinctive pathologies.
The majority of cathepsin family members showed upregulation in an advanced yet stable segment compared with a ruptured segment of a carotid lesion of the same patient. CatC was among the top 3 of upregulated cathepsins ( Figure 1A) . CatC was also significantly upregulated on the protein level in ruptured lesions and was largely confined to inflammatory foci within the plaque. To study the role of CatC, a mouse model of atherogenesis was used. In the collar-induced atherosclerotic lesion model, a semiconstrictive but nonstenotic collar is placed around the carotid artery in a hyperlipidemic background. The lesions are the result of perturbed hemodynamics, and not of restenosis. Several papers have shown that the processes and mechanisms that are involved in collar-induced atherosclerosis are also involved in longitudinal, age-induced models of atherosclerosis, that is, inflammation, lipid metabolism, and intraplaque hemorrhage. [25] [26] [27] [28] [29] Mouse models model human atherogenesis, but show inherent differences with the human pathophysiology, 30 the most striking of which being the virtual absence of plaque rupture; therefore, this study focused on the role of CatC in early and more advanced stages of disease progression. Our experimental mice study suggested that CatC deficiency (or therapeutic intervention in its activity) during atherogenesis may be beneficial. Given limitations intrinsic to the animal model, extrapolating these findings to the human situation should be done cautiously, especially as CatC proteolysis could contribute to processes that are relevant to vulnerable plaque formation and rupture (eg, hemorrhage, coagulation, cap erosion, fibrinolysis). Also, human-ruptured plaques likely have entered an active wound-healing phase, and the overexpressed CatC might well be involved in the healing process after plaque rupture. Importantly, in the mouse model, the effect of CatC deficiency on disease progression was not only based on collar-induced atherosclerotic lesions, but also on other locations that were investigated (aortic arch and descending aorta, aortic root). Collectively, these data suggested that CatC deficiency affected lesion progression, with some site specificity, because the effect in the advanced lesions of the aortic arch was less evident. CatC was abundantly expressed in mouse plaques, where it colocalized mainly with foam cells and plaque macrophages. Because intimal CatC expression and CatC activity were almost absent in chimeric mice with hematopoietic CatC deficiency, we may infer that plaque CatC is of leukocyte origin.
The reduced plaque formation during CatC deficiency was similar to murine intervention studies with other cathepsin family members, such as CatS and CatK. 19, 20 Similar to leukocyte CatS deficiency, CatC deficiency appeared to prevent plaque progression beyond the early macrophage-rich stage. CatC deficiency did not affect CatK expression but slightly induced CatS expression. As the chromosomal location of both genes (chr.3, 3 F2.1) differs from that of CatC (chr.7), CatS upregulation may be compensatory, rather than a transgenesis artifact.
The lack of effect of CatC deficiency on plaque collagen content led us to investigate peripheral effects of CatC on leukocyte function. Because no overt differences were seen in granulocyte and monocyte counts, we focused on effects of CatC on monocyte/macrophage differentiation. CatC expression was downregulated in IL-4-primed macrophages and upregulated in IFN-γ-primed macrophages. In this regard, the CatC expression profile mimics that of established M1 markers, such as IL-19 and iNOS, and the proinflammatory proteases MMP9 and MMP12. CatC expression was previously reported to be responsive to IRF8 and PU.1, suggesting a link to macrophage differentiation and interferon signaling. 31 The most intriguing finding, however, was that CatC deficiency dampened M1 but not M2 polarization in vitro, the net effect being macrophage skewing toward M2. Although macrophage motility on a gelatin matrix was not affected during CatC inhibition, efferocytosis of apoptotic cells by CatC-deficient macrophages was impaired during proinflammatory conditions. The CatC deficiencyassociated reduction in necrotic core expansion seems to confirm that apoptotic cell handling is not notably defective in CatC −/− plaque macrophages. The blunted LPS response on efferocytosis in CatC deficiency is interesting and may suggest interference with Toll-like receptor signaling, in analogy to the previously reported inhibition of TLR9 signaling by CatK 32 for protein kinases. 33 Direct evidence for CatC for such interaction is, however, lacking. Despite the clear in vitro polarization phenotype, a concomitant shift in local plaque macrophage polarization was not observed, although this was assessed using a single M1 and M2 marker and only at 1 (end) timepoint. This is possibly related to the overt dominance of M1 macrophages in early and more advanced stages of plaque development, as also reported by Stöger et al. 34 Of note, this does not exclude that CatC deficiency could be associated with a dampened M1 polarization stage in plaques.
In relation to the M2 shift in vitro, increased eotaxin plasma levels and a concomitant increase in spleen eotaxin and TGFbeta expression were noted. Eotaxin is generally viewed as prototypical Th2 cytokine, 35 and compatible with this notion, CatC deficiency led to reduced CD4/CD8 ratios in blood and spleen and elevated GATA3, but not TBX21, expression in spleen T cells. Whether Th2-favored immune responses ameliorate or worsen atherosclerosis is still subject to controversy 36 ; thus consequently, whether the CatC deficiencyassociated Th2 shift affords atheroprotection remains to be determined.
Of note, as shown by Devadas et al, a critical step in Th2/Th1 cell differentiation involves selective granzyme B-mediated apoptosis of Th2 cells. 37 Hence, leukocyte deficiency in CatC, a key enzyme in granzyme activation, could well favor survival of Th2 cells. Although conceivable, further studies will be required to establish this pathway. The CD4 + T cell pool was enriched in CD25 +
Foxp3
+ Treg numbers, and in agreement, FoxP3 expression by spleen T cells was elevated as well. As demonstrated in numerous studies, Tregs display atheroprotective activity (for a review, see Ref. 38) . Whether this effect is directly attributable to CatC deficiency remains to be elucidated.
In conclusion, we are the first to show that CatC gene and protein expression is upregulated in atherosclerotic lesions of both mice and man. Its expression seems confined to inflammatory foci within the plaque and, in particular, involve intimal foam cells and macrophages. CatC deficiency led to an impaired atherogenic response. Although effects of CatC deficiency on plaque matrix composition seemed subtle, our studies unveiled an unexpected feedback effect on macrophage activation programs in vitro, as well as on T helper cell differentiation. In that regard, our findings could open the way for selective tuning of innate and adaptive immune responses, relevant to chronic immune diseases, such as atherosclerosis.
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